#pharma
US pharma giant Walgreens to set up GCC in Chennai
Walgreens establishes its first Global Capability Centre in Chennai, creating over 250 high-value jobs in technology and operations.
Alkem Laboratories launches NeuCeno for partial-onset seizures in adults
The once-daily oral therapy is available in five strengths, with clinical studies showing reductions in seizure frequency among adults with uncontrolled focal seizures
India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore
2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world…
India 20 pc share in global generic exports provides strong platform for growth : Expert
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?
Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remain…
India could be on the radar for AstraZeneca’s oral GLP-1 drug: MD
AstraZeneca’s MD hints at India’s potential inclusion in global trials for its promising oral GLP-1 weight loss and diabetes drug.
India - Oman CEPA takes effect : 98 % duty - free access opens doors for textiles , pharma , MSMEs : Piyush Goyal
Importance of India is now : US envoy Sergio Gor highlights Pharma trust , Pax Silica partnership
From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoil
Indian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite market volatility and global concerns. Sectors like telecom, auto, and pharma saw significant gains. This signals resilien…
Cipla is aiming for 40 - 50 global product filings in three years , says MD Achin Gupta
Granules India Shares Jump 5 % To Fresh ₹800 High , Pharma Stock Delivers Nearly 40 % Return In 3 Months
Asia Drug Development Beyond China Strategic Intelligence Report 2026: Pharma R&D and Deal Trends in South Korea, Japan, and India
Asia's drug development market opportunities include China's leadership, the dominance of small molecules and oncology, and increased clinical trial activity in South Korea and India. Japan focuses on multinational trials, with licensing preferred over M&A. O…
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength. These sectors are hitting new highs, driven by structura…
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Marks Lupin's Debut in the Chinese Market MUMBAI, India and BEIJING and NAPLES, Fla., May 22, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China'…
Recent FTAs could erode our policy space
red flags. Recent trade pacts with UK and EU appear to boost market access. But the fineprint suggests trouble for MSMEs, pharma and digital policymaking
Cold Chain Monitoring Market Expands Rapidly as Pharma, Vaccine, and Food Logistics Demand Advanced Monitoring Solutions | Valuates Reports
BANGALORE, India, May 22, 2026 /PRNewswire/ -- What is the Market Size of Cold Chain Monitoring? According to Valuates Reports, The global Cold Chain Monitoring market was valued at USD 7414 Million in 2025 and is anticipated to reach USD 15390 Million by 203…
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Marks Lupin's Debut in the Chinese Market MUMBAI, India and BEIJING, May 22, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China's National Medical Product…
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Marks Lupin's Debut in the Chinese Market MUMBAI, India and BEIJING, May 22, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China's National Medical Product…
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian compa…
Analytical Instrumentation Market to Hit USD 98.50 Billion by 2035 as Precision Diagnostics and Pharma R&D Fuel Growth – SNS Insider
U.S. Market to Surpass USD 29.95 Billion by 2035, While Europe Market Set to Hit USD 27.94 Billion Driven by Regulatory Compliance and Advanced Healthcare Infrastructure. U.S. Market to Surpass USD 29.95 Billion by 2035, While Europe Market Set to Hit USD 27.…
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
The wearables in pharma & biotech market is forecasted to grow from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%. This rapid growth is fueled by advances in biosensor technology, miniaturization, and digitization, supported by stro…
Novo Nordisk’s next obesity battlefront: Winning beyond America
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.
Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vial
Eli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in India. Eli Lilly has launched Lormalzi, a new monthly treatment for early Alzheimer's disease. This drug targets amyloi…
Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
MUMBAI, India and NAPLES, Fla, May 13, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug…
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. This cutting-edge suite will significantly enhance the company's ability t…
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. This cutting-edge suite will significantly enhance the company's ability t…
Stocks in news: Groww, Dr Reddy's, Waaree Energies, Lenskart, SBI
Markets experienced a sharp risk-off session on Monday, with indices declining amid broad selling. Investors are advised to avoid aggressive index bets and await clearer directional signals. Pharma and healthcare stocks remain preferred, while dips in energy …
Fibromyalgia Market Competitive Landscape Report 2026: Market is Not Likely to See Any Major Shifts in the Near Term, with No Products in Pre-registration or Phase III Development.
The main market opportunities in fibromyalgia therapeutics include the significant number of anticipated cases in India by 2029, a limited treatment landscape with few approved drugs and generics dominance, and untapped potential in early-stage clinical asset…
Son rise at Sun: Decoding the architecture of Dilip Shanghvi’s global empire
With a bold $11.75 billion bet on Organon, Dilip Shanghvi is hedging a decade of US stagnation and quietly commissioning an empire for a son who would rather let the numbers do the talking.
Indian firms commit $20.5 billion investment in US; Pharma dominates with $19.1 billion
The pharmaceutical sector accounted for the vast majority of the financial commitment, with planned investments exceeding $19.1 billion, led by Sun Pharmaceutical Industries Ltd